Inquiry Basket
N-Me-L-Ala-maytansinol - CAS 77668-69-0 Catalog number: BADC-00687
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
N-Me-L-Ala-maytansinol is a hydrophobic, cell permeable payload used in the preparation of antibody-drug conjugate (ADC).
Category
ADCs Cytotoxin
Product Name
N-Me-L-Ala-maytansinol
CAS
77668-69-0
Catalog Number
BADC-00687
Molecular Formula
C32H44ClN3O9
Molecular Weight
650.17
Target
Ordering Information
| Catalog Number | Size | Price | Quantity |
|---|---|---|---|
| BADC-00687 | 500 mg | $1999 |
Description
N-Me-L-Ala-maytansinol is a hydrophobic, cell permeable payload used in the preparation of antibody-drug conjugate (ADC).
Synonyms
AP3 Intermidate 1; Maytansinol 3-(S)-α-N-methylaminopropionate; Maytansine, N2'-deacetyl-; (1S,2R,3S,5S,6S,16Z,18Z,20R,21S)-11-Chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10(26),11,13,16,18-pentaen-6-yl N-methyl-L-alaninate; Maytansinol-Ala
IUPAC Name
[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] (2S)-2-(methylamino)propanoate
Canonical SMILES
CC1C2CC(C(C=CC=C(CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)CC(C4(C1O4)C)OC(=O)C(C)NC)C)C)OC)(NC(=O)O2)O
InChI
InChI=1S/C32H44ClN3O9/c1-17-10-9-11-24(42-8)32(40)16-23(43-30(39)35-32)18(2)28-31(4,45-28)25(44-29(38)19(3)34-5)15-26(37)36(6)21-13-20(12-17)14-22(41-7)27(21)33/h9-11,13-14,18-19,23-25,28,34,40H,12,15-16H2,1-8H3,(H,35,39)/b11-9+,17-10+/t18-,19+,23+,24-,25+,28+,31+,32+/m1/s1
InChIKey
ANHBJISROJTYCJ-MSKZWLSNSA-N
Density
1.31±0.1 g/cm3 (Predicted)
Solubility
Soluble in DMSO
Appearance
Solid Powder
Purity
≥95%
Shipping
Room temperature, or blue ice upon request.
Storage
Store at 2-8°C for short term (days to weeks) or -20°C for long term (months to years)
Boiling Point
849.5±65.0°C (Predicted)
1.Antibody drug conjugates of cleavable amino-alkyl and aryl maytansinoids
Nittoli T, Kelly MP, Delfino F, Rudge J, Kunz A, Markotan T, Spink J, Chen Z, Shan J, Navarro E, Tait M, Provoncha K, Giurleo J, Zhao F, Jiang X, Hylton D, Makonnen S, Hickey C, Kirshner JR, Thurston G, Papadopoulos N
Natural products have been used for many medicinal purposes for centuries. Antibody drug conjugates (ADCs) have utilized this rich source of small molecule therapeutics to produce several clinically useful treatments. ADCs based on the natural product maytansine have been successful clinically. The authors further the utility of the anti-cancer natural product maytansine by developing efficacious payloads and linker-payloads for conjugating to antibodies. The success of our approach was realized in the EGFRvIII targeting ADC EGFRvIII-16. The ADC was able to regress tumors in 2 tumor models (U251/EGFRvIII and MMT/EGFRvIII). When compared to a positive control ADC, the efficacy observed was similar or improved while the isotype control ADCs had no effect.
